Daridorexant and Verapamil hydrochloride (İsoptin SR 240 mg): interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Moderate CYP3A4 inhibition can increase daridorexant exposure.
Clinical significance and safety
Verapamil may increase daridorexant exposure through moderate CYP3A4 inhibition. The label requires a reduced maximum daridorexant regimen with moderate inhibitors. A prescriber should check the combination, including next-day drowsiness and falls risk, before treatment is used together.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.